Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (630)	8/21/2000 9:52:35 PM
From: Jeffrey S. Mitchell	Read Replies (2) \| Respond to of 12465

Re: BXM Class Action Suits The civil complaint charges that about half of the more than 33,000 postings on Yahoo!'s BMX board were from the trio, who used a variety of false names. The negative messages may have been a factor in the drop of Biomatrix stock from $35 to $21 a share, Massachusetts Secretary of State William Galvin noted in a press release. Anyone who held a short position, a technique used to take advantage of an anticipated decline in the price of a security, would benefit from a significant drop in their price. ----- This certainly will be an interesting case to follow. I note that there are at least five class action suits filed against BXM. Are all these law firms basing their suits on information they obtained solely from the three people who allegedly posted 16,000+ messages on Yahoo? I doubt it. Yet the Massachusetts Securities Division apparently thinks there was manipulation to get the price down. ===== Schiffrin & Barroway, LLP, Announces Class Periods and Deadlines for Securities Fraud Actions BALA CYNWYD, Pa., Aug 21, 2000 (BUSINESS WIRE) -- Schiffrin & Barroway, LLP has recently filed class action complaints against certain companies on behalf of investors nationwide. These actions allege violations of the federal securities laws. If you purchased the common stock of any of these companies during the relevant time period (the "Class Period"), your legal rights may be affected by these actions. They include: Class Period Deadline ------------ -------- Biomatrix, Inc. 07/20/99 - 04/25/00 09/19/00 (NYSE: BXM chart, msgs) siliconinvestor.com ===== Milberg Weiss Announces Securities Class Periods NEW YORK, Aug 20, 2000 (BUSINESS WIRE) -- The following is an announcement by the law firm of Milberg Weiss Bershad Hynes & Lerach, LLP: Milberg Weiss (http://www.milberg.com) gives notice to purchasers of the following securities for the following periods: CORPORATION PERIOD ----------- ----------------- Biomatrix, Inc. (NYSE: BXM chart, msgs - chart, msgs news chart, msgs) 7/20/99 - 4/25/00 To sign up on-line: milberg.com siliconinvestor.com ===== Notice to Investors Concerning Pending Lawsuits, by Cauley & Geller, LLP SAN DIEGO, Aug 18, 2000 (BUSINESS WIRE) -- Cauley & Geller, LLP, a law firm with offices in Little Rock, Arkansas, Boca Raton, Florida and San Diego, California which has specialized in representing shareholders in class actions for seven years, gives notice to purchasers of the following securities for the following periods: CORPORATION PERIOD Biomatrix, Inc. (NYSE: BXM chart, msgs) 07/20/99 - 04/25/00 siliconinvestor.com ===== Investors File Class Actions Seeking Returns of Losses Announces The Law Office of Leo W. Desmond WEST PALM BEACH, FLA., Aug 12, 2000 (BUSINESS WIRE) -- The Law Office of Leo W. Desmond (http://www.SecuritiesAttorney.com) today announced that securities actions requesting class action certification have been initiated in various courts alleging violations of federal and/or state securities laws on behalf of purchasers of the following securities for the following class periods: Biomatrix, Inc. (NYSE: BXM chart, msgs) 07/20/99 to 04/25/00 siliconinvestor.com ===== Law Offices Of Charles J. Piven, P.A. Announces Securities Class Periods BALTIMORE, Jul 26, 2000 (BUSINESS WIRE) -- Law Offices Of Charles J. Piven, P.A. today announced that securities actions requesting class action status have been initiated on behalf of purchasers of the following securities during the following periods: Class Period Symbol Exchange Biomatrix, Inc. 07/20/99-04/25/00 BXM NYSE siliconinvestor.com ===== ===== Cauley & Geller, LLP Announces Class Action Lawsuit Against Biomatrix, Inc. Seeking Damages On Behalf of Shareholders BOCA RATON, Fla., Aug 16, 2000 (BUSINESS WIRE) -- The Law Firm of Cauley & Geller, LLP announced today that it has filed a class action in the United States District Court for the District of New Jersey on behalf of all individuals and institutional investors that purchased the common stock of Biomatrix, Inc. ("Biomatrix" or the "Company") (NYSE: BXM chart, msgs) between July 20, 1999 and April 25, 2000, inclusive (the "Class Period"). The complaint charges that the Company and certain of its officers and directors violated the federal securities laws by providing materially false and misleading information about the Company's business, prospects and operations. Specifically, the complaint alleges that the defendants knowingly or recklessly misrepresented the efficacy of its leading product, Synvisc, a gel-like substance used in the treatment of osteoarthritis. Plaintiffs allege that defendants artificially inflated reported sales of Synvisc and exaggerated the medical community's acceptance of the product. As a result of these false and misleading statements the Company's stock traded at artificially inflated prices during the class period. When the truth about the Company was revealed, the price of the stock dropped significantly. Cauley & Geller, LLP has substantial experience representing investors in securities fraud class action lawsuits such as this. The firm has offices in Florida, Arkansas and California, but represents shareholders from throughout the nation. If you have any questions about how you may be able to recover for your losses, or if you would like to consider serving as one of the lead plaintiffs in this lawsuit, you must meet certain requirements and take appropriate action by September 19, 2000. You are encouraged to call or e-mail the Firm or visit the Firm's website at www.classlawyer.com. Contact: Cauley & Geller, LLP, Boca Raton Sue Null, Jackie Addison or Sharon Jackson Toll Free: 1-888-551-9944 E-mail: Cauleypa@aol.com TICKERS: NYSE:BXM siliconinvestor.com ===== Shareholder Class Action Filed Against Biomatrix, Inc. by the Law Firm of Schiffrin & Barroway, LLP BALA CYNWYD, Pa., Aug 16, 2000 (BUSINESS WIRE) -- The following statement was issued today by the law firm of Schiffrin & Barroway, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the District of New Jersey on behalf of all purchasers of the common stock of Biomatrix, Inc. (NYSE: BXM chart, msgs) from July 20, 1999 through April 25, 2000 inclusive (the "Class Period"). If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin & Barroway, LLP (Marc A. Topaz, Esq. or Robert B. Weiser, Esq.) toll free at 888/299-7706 or 610/667-7706, or via e-mail at info@sbclasslaw.com. The complaint charges Biomatrix and certain of its officers and directors with issuing false and misleading statements concerning the Company's business, prospects and operations. Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin & Barroway, LLP, who has significant experience and expertise prosecuting class actions on behalf of investors and shareholders. For more information on Schiffrin & Barroway, please visit our website at www.sbclasslaw.com. If you are a member of the class described above, you may, not later than September 19, 2000 move the Court to serve as lead plaintiff of the class, if you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements. Contact: Schiffrin & Barroway, LLP Marc A. Topaz, Esq. Robert B. Weiser, Esq. 888/299-7706 (toll free) or 610/667-7706 E-mail: info@sbclasslaw.com TICKERS: NYSE:BXM siliconinvestor.com ===== Wolf Haldenstein Adler Freeman and Herz LLP Announces Commencement of Securities Case Against Biomatrix, Inc. and Certain Directors and Officers NEW YORK, Aug 7, 2000 (BUSINESS WIRE) -- The following is an announcement by the law firm of Wolf Haldenstein Adler Freeman and Herz LLP: Wolf Haldenstein Adler Freeman & Herz LLP commenced a class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Biomatrix, Inc. ("Biomatrix" or the "Company") (NYSE: BXM chart, msgs - chart, msgs News chart, msgs) between July 20, 1999 and April 25, 2000, inclusive (the "Class Period"). A copy of the complaint filed in this action is available from the Court, or can be viewed on the Wolf Haldenstein website at www.whafh.com. The complaint alleges that the Company and certain of its officers and directors, namely Endre A. Balazs, CEO, Dir. & chief scientific officer, and Rory B. Riggs, Pres. and Dir., violated the federal securities laws by providing materially false and misleading information about the Company's business, earnings growth and financial condition during the Class Period. Specifically, Biomatrix manufactures, markets and sells a viscoelastic product called Synvisc, a gel-like substance that is injected into arthritic knees to postpone the necessity of, or even provide a substitute for, knee-replacement surgery. Throughout the Class Period, defendants artificially inflated the Company's reported net revenue, net income, earnings per share, and product sales of Synvisc through the twin practices of reporting revenue upon the shipment of product to distributors and stuffing the product pipeline with excess inventory. Defendants further misrepresented that demand for Synvisc was increasing and that there was growing acceptance within the medical community for Synvisc "as an effective therapy" for osteoarthritis. Defendants knew, however, that the medical community was increasingly doubtful that Synvisc was a viable medical treatment, as numerous studies had shown that Synvisc was no more effective than a placebo or salt water injections in treating osteoarthritis, and might actually cause significant, long-term, adverse effects, such as cartilage damage. As Synvisc's limitations became increasingly obvious to them, the individual defendants determined to cash out their investments but wanted to do so without driving down the price of their shares in the process. To this end, defendants engineered a combined cash and stock merger of the Company into Genzyme Corporation,announcing the Company's agreement to the merger on March 6, 2000. That announcement sought to manage the disclosure that due to the buildup of inventory in the channel, first-quarter sales might not be as robust as defendants had indicated just weeks earlier. Thus during a conference call with industry analysts, defendant Riggs was careful to state that there would still be growth for the quarter, but less than defendants had expected. It was not until April 25, 2000, when Biomatrix announced first-quarter revenues for 2000, that defendants disclosed for the first time the effect that channel-stuffing throughout 1999 had had on its year 2000 revenues and earnings. The Company announced first-quarter revenues of $16.7 million and net income of $0.5 million or $0.02 per diluted share. By this time the Company's share price had dropped to $19 15/16, down 85% from a Class Period high of $37 on March 1, 2000. If you purchased Biomatrix securities between July 20, 1999 and April 25, 2000, you may, no later than September 19, 2000, request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wolf Haldenstein, or other counsel of your choice, to serve as your counsel in this action. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. In order to serve as lead plaintiff, you must meet certain legal requirements. If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP at 270 Madison Avenue, New York, New York 10016, by telephone at (800) 575-0735 (Fred Taylor Isquith, Esq., Gregory M. Nespole, Esq., Brian S. Cohen, Esq., or Michael Miske via e-mail at classmember@whafh.com, whafh@aol.com, nespole@whafh.com, Gnespole@aol.com, or our website at www.whafh.com. All e-mail correspondence should make reference to BXM -------------------------------------------------------------------------------- Contact: Wolf Haldenstein Adler Freeman & Herz LLP, New York Fred Taylor Isquith, Esq., Gregory M. Nespole, Esq., Brian S. Cohen, Esq., or Michael Miske 800/575-0735 classmember@whafh.com whafh@aol.com nespole@whafh.com Gnespole@aol.com www.whafh.com TICKERS: NYSE:BXM siliconinvestor.com ===== - Jeff

To: Mama Bear who wrote (630)	8/22/2000 1:56:54 AM
From: Jeffrey S. Mitchell	Read Replies (1) \| Respond to of 12465

Re: 8/21/00 - [BXM] Complaint charges three men targeted companies through Internet Complaint charges three men targeted companies through Internet By Steve LeBlanc, Associated Press, 08/21/2000 BOSTON -- Three men targeted the stock of a biotechnology company by posting tens of thousands of false and misleading statements on an online message board, the Secretary of State's Office charged in a complaint filed Monday. The men allegedly began posting messages last year in an effort to drive down the stock of Biomatrics Inc., which is in the process of being acquired by Cambridge-based Genzyme Corp. From April to May, the company's stock fell from $35 a share to about $21. In the past 52 weeks, the stock's price has ranged from $17 to $38.50 per share. It was down about 19 cents a share on Monday, closing at $21.125 a share. The three men -- brothers Raymond and Richard Costanzo of North Carolina, and Ephraim Morris of Arizona -- were named in a complaint filed by Massachusetts Secretary of State William Galvin with the state's Securities Division. The three men posted the statements on message boards on the Yahoo! Web site, the complaint said. In one of the messages, Raymond Costanzo warned investors that Biomatrics wanted to "steal your money with their endless lies, hype and false promises," according to Galvin's office. In another, he predicted the stock prices for Biomatrics would fall and advised investors to "run for the hills from these fraudulent stocks," Galvin's office said. The three also claimed patients were being injured and drugs developed by Biomatrics were not working, Galvin's office said. Richard and Raymond Costanzo did not immediately return a phone call. A message left for an E. Morris was also not immediately returned. Biomatrics had previously filed a lawsuit against the three, according to Bo Piela, a spokesman for Genzyme. It was not immediately know if the Securities and Exchange Commission also was looking into the matter. Genzyme is acquiring Biomatrics and merging it with two existing Genzyme subsidiaries to create Genzyme Biosurgery, a new division of the company designed to develop and market biotechnology products used for surgical procedures, Piela said. Genzyme has laboratories in Framingham. Galvin's office is seeking an administrative fine, an immediate cease and desist order and a requirement that the three give up any profits they may have gained from the alleged stock manipulation. Fines can run up to $10,000 for each infraction. The complaint does not say whether the men gained financially from the messages they accused of posting. Rulings by the Securities Division, which is a unit within the Secretary of State's Office, do not carry the weight of criminal law. However, the complaint could be referred to the state Attorney General's Office if the three men are found to have violated a cease and desist order. The complaint charged the three men not only used several user names on the message boards to post negative comments, but that they slightly altered the names of users who had been friendly to the stocks in order to create the impression that those users had changed their minds. Since April 1999, about half of the 33,000 messages about Biomatrics came from the three men, according to the complaint. A message left for a Biomatrics spokeswoman was not immediately returned Monday. digitalmass.com

To: Mama Bear who wrote (630)	8/22/2000 2:26:55 PM
From: Jeffrey S. Mitchell	Read Replies (1) \| Respond to of 12465

Re: 8/00 - [BXM] Massachusetts Securities Division Complaint in the matter of Costanzo, Costanzo, and Ephraim (Part 1 of 2) COMMONWEALTH OF MASSACHUSETTS OFFICE OF THE SECRETARY OF THE COMMONWEALTH SECURITIES DIVISION ONE ASHBURTON PLACE, 17TH FLOOR BOSTON, MASSACHUSETTS 02108 ________________________________________________ ) IN THE MATTER OF: ) ) RAYMOND V. COSTANZO ) RICHARD V. COSTANZO ) DOCKET NO. E-00-029 EPHRAIM EPHRAIM ) ) RESPONDENTS. ) ________________________________________________) ADMINISTRATIVE COMPLAINT I. PRELIMINARY STATEMENT The Enforcement Section of the Massachusetts Securities Division of the Office of the Secretary of the Commonwealth (the "Enforcement Section" and the "Division" respectively) files this complaint (the "Complaint") in order to commence an adjudicatory proceeding against the Respondents for violating M.G.L. c. 110A, the Massachusetts Uniform Securities Act (the "Act"), and 950 CMR 10.00 et seq. (the "Regulations"). The Division alleges that since April 1999, the Respondents, individually and in concert, have posted materially misleading and false information on the Yahoo! message boards for Biomatrics, Inc. ("BXM"), Genzyme Corporation’s Tissue Repair and Surgical Products Division ("GZTR") and Genzyme Corporation’s Biosurgery Division ("GZSP") in an attempt to manipulate the price of those stocks. Therefore, the Division seeks an Order of the Division imposing an administrative fine on Respondents in such an amount and upon such terms and conditions as the Director or Hearing Officer may determine; requiring Respondents to disgorge any profits resulting from the manipulation of the stock prices; requiring Respondents permanently to cease and desist from violations of the Act and Regulations; and to take any other actions which may be in the public interest and necessary and appropriate for the protection of investors. II. JURISDICTION AND AUTHORITY 1. The Massachusetts Securities Division is a division of the Office of the Secretary of the Commonwealth with jurisdiction over matters relating to securities as provided for by the Act. The Act authorizes the Division to regulate the offers and/or sales of securities and those individuals offering and/or selling securities within the Commonwealth of Massachusetts. 2. Pursuant to the Act and M.G.L. c. 30A, the Division has the authority to conduct an adjudicatory proceeding to enforce the provisions of the Act and all regulations and rules promulgated thereunder. This proceeding is brought in accordance with §§ 101 and 407A of the Act and corresponding Regulations. 3. The Division specifically reserves the right to amend this Complaint and/or bring additional administrative complaints to reflect information developed during the current ongoing investigation. III. RESPONDENTS 4. Raymond V. Costanzo ("Raymond") is an individual whose last known address is 300 Woodcroft Parkway, #23B, Durham, NC 27713. According to Division records, Raymond has never been registered with the Division. Raymond uses, among others, the following message board user names: cd_438; allergic tochickenbits; onecutelittlegirl; cd_43eighttt; tea_pot_dome; spirit_of_ed_leshiner; computersdotcom; ef_438; iop_tom; rvcrvcrvc; rvcrvcrvc_1964; wtc_federalway; fg_438; i_should_have_listened; the_hunt_for_das_boot; and joe_everyman. 5. Richard V. Costanzo ("Richard") is an individual whose last known address is 300 Woodcroft Parkway, #23B, Durham, North Carolina, 27713. According to Division records, Richard has never been registered with the Division. Richard uses, among others, the following message board user names: meddraman; meddra_2k; meddra_2000; Meddra_man; 1_0000; one_year_of_the_bxm_police; weintraub_s; owned_cvd_since_the_beginning; and 1_00000. 6. Ephraim Morris ("Ephraim") is an individual whose last known address is 250 S. Elizabeth Way, #1046, Chandler, AZ 85225. According to Division records, Ephraim has never been registered with the Division. Ephraim uses, among others, the following message board user names: VoteRep; voterep_returns; vr_loves_the_nra; jenti_is_pro_life; jenti_is_very_pro_life; vote_Republican; vote_Republican_2000; missyx_2000; rnouth2857; connie_1976; bfriendly2me2; wens_old_guy; and supoena_the_qc_log_books. IV. RESPONDENTS’ CONDUCT A. Background 7 BXM is a Delaware corporation with a principal place of business in New Jersey. Its stock is traded publicly on the New York Stock Exchange ("NYSE") under the ticker symbol BXM. GZTR and GZSP are divisions of Genzyme Corporation, a Massachusetts corporation ("GENZ"). Both stocks trade publicly through the National Association of Securities Dealers Automated Quotation ("NASDAQ") system under the ticker symbols GZTR and GZSP. On or about March 6, 2000, GENZ entered into an agreement to merge GZBS and GZTR with BXM. 8. Since April of 1999, Raymond, Richard and Ephraim, using their various user names have attempted to manipulate the price of the stock of BXM by posting a series of false and misleading statements on the Yahoo! Finance message board for BXM stock. 7. Since March 2000, Raymond, Richard and Ephraim, using their various user names have attempted to manipulate the price of the stock of GZSP and GZTR by posting a series of false and misleading statements on the individual Yahoo! Finance message boards for GZSP and GZTR stock. 8 All three Respondents have engaged in a comprehensive scheme to artificially depress the price of the stock through the medium of the Yahoo! Finance message boards. Their tactics included repeatedly sending the same negative message to the three message boards (BXM, GZSP, and GZTR), sometimes within the same day and sometimes over a period of weeks. In addition, each of the Respondents actively employed five or more user names to simulate negative discussions of each of the stocks and to create the illusion that many different posters also felt negatively about the stocks. The Respondents also altered the user names of posters who had historically been positive about the stock by slightly altering their usernames, usually by one letter or number and then making negative posts under the altered user names creating the illusion that the positive posters had changed their minds and now hold a negative opinion about the stock. 9. The Respondents spent a large part of every day since April 1999, responding to posts from legitimate users and creating more negative posts. (Antalik Aff. at 7.) Out of over 33,000 messages on the Yahoo! Finance message boards for BXM, GZTR and GZSP, the Respondents’ posts comprise approximately 50% of the posted messages. (Antalik Aff. at 5.) The overall effect of the numerous posted messages has been to create a falsely negative atmosphere that subsequently influenced investors’ decisions to buy or sell the stock of BXM, GZTR, and GZSP. In April of 1999, BXM stock traded at approximately $35 per share and is currently trading around $21 per share. B. Statements made by Raymond 10. Raymond under various usernames has posted the following statements on the Yahoo! Finance message boards for BXM, GZSP and GZTR: (See Exhibit A for complete postings and a list of locations and dates where the same or substantially similar message was posted.) Titled: BXM to fall sharply tomorrow: With this quarter’s earnings and sales numbers now released, every intelligent investor is RIGHT NOW placing their sell orders. DO YOU want to be the last one out? Remember, the last one out LOSES the money. We have watched as, time and time again, doctor’s have rejected Biomatrix’s pleas that they use Synvisc. We have handled and tested the chemistry of Synvisc (and all other Biomatrix products) and understand better than anyone that it is glorified sugar water MARKETED as medicine (and yet doctors reject Synvisc, hmmmm). We have read the "clinical trials" that can only marginally determine that Synvisc is only better than NOTHING at all. We know the CEO, president, and other senior management personnel on a PERSONAL level. They are amoral, evil swindlers who have sold their souls for a promise of wealth. We have watched as Synvisc was "launched" into the European market only to fall FLAT on its face (as Synvisc has done in ALL the markets that it has been "launched" into). And we have watched as financial institutions ( with a lot of help from this board) have HYPED this stock with absurd PROMISES that BXM hasn’t and will never be able to keep. It is not surprising that Synvisc should come under attack by federal authorities for unsafe levels of "endotoxins". It goes hand-in-hand with the continuous microbiology failures Synvisc has suffered. It works like this: 1) Synvisc is manufactured. 2) Synvisc is tested for microbial growth ("mold"). 3) Synvisc is found to contain unacceptably high numbers of living microbe colonies (colonies of growing "mold"). 4) Synvisc is heated to kill these microbes. 5) The "mold" is now dead, but all those dead "mold" cells continue to float in Synvisc. Those "dead mold cells" are called endotoxins. And high levels of endotoxins are just as dangerous as high levels of living "mold" cells. If Synvisc was consumed orally it wouldn’t be a problem. Stomach acid would simply digest those "dead mold cells". But when injected into a warm knee, those dead cells only provide food for other, living, parasites. This is why they are unacceptable in a "sterile" product. Yet Biomatrix has, and continues to, release material which has been deemed UNFIT FOR HUMAN USE by their own specifications. Specifications which are summarily ignored if it means losing money. THESE are the monsters that you are investing in. THESE are the monsters which we are trying to stop. I worked at Biomatrix for over 6 years and reported directly to Dr. Balazs himself. I KNOW exactly what kind of dangerous SCAM Biomatrix is. And, slowly, the rest of the world is catching up. This was originally posted by wtcrane1: "Just found out some interesting information about Synvisc. Apparently the Swedish government is investigating Synvisc due to the high number of patients who are experiencing sever acute inflammatory reactions after the injections. The patients with these reactions are reported to have experienced pains, swelling and difficulties in walking. According to the government agency report, " in many cases the patient has been admitted to hospital for suspected infectious arthritis". This sounds very similar to the reactions to Synvisc that are increasingly being seen right here in the U.S. The Medicines Agency there is theorizing that the "quantity of endotoxins" in Synvisc might be a contributing factor to these cases. They are "investigating whether the side effects can be dependant upon a handling or quality problem or a combination of these." Source: Journal of the Swedish Medicinal Products Agency; "Information" 7:99 of November 1999." Title: Contaminated Synvisc is a FACT All these testing failures I speak of, and the subsequent releases that followed, DID OCCUR! Of course, it’s not the kind of thing that Biomatrix is likely to brag about, is it. Yet it DOES explain the numerous adverse reactions DOCUMENTED BY DOCTORS. AND the constant observation by the FDA. Two things that Biomatrix will deny as long as it’s not in a court of law (something you angry, class action investors should keep in mind when issuing subpoenas). NOT TO MENTION ALL THE INJURED PATIENTS! Hmmmm, now THERE’s an idea. If YOU are a patient who has suffered an adverse reaction with Synvisc, SUE BIOMATRIX. Force them to release the QC testing records to support your case, and DON"T FORGET TO DEMAND MILLIONS OF DOLLARS IN DAMAGES. Just a thought. I would NEVER use Synvisc or invest in this doomed stock so I am unlikely to be sueing (sic) Biomatrix anytime soon. But everyone else should keep it in mind. Title: More proof of the FAKE ‘merger’ How can Tissue Repair make a deal with Sentron Medical exchanging stock (equity) for licensing rights BEFORE the "merger" and WITHOUT consulting their "partners"? Or doesn’t Tissue Repair give a damn? Indeed, Genzyme Tissue Repair is continuing their business plan AS IF THERE IS NO "MERGER" SCHEDULED. But then, Genzyme Tissue Repair already knows that this "merger" is just a financial institution ploy to STEAL INVESTOR’S MONEY. Title: A year’s worth of declining earnings It is clear that Biomatrix is collapsing. The SCAM CALLED SYNVISC is rapidly unraveling and both sales and earnings reflect this. BXM IS A SINGLE DIGIT STOCK. Those that accept that FACT will protect their money. Anyone that tells you that this stock will increase in value is trying to STEAL YOUR MONEY. You have been warned. Title: 3 declining companies merging together? Anyone that puts their money into BXM, GZTR, or GZSP will lose it as all three companies continue to decline. Title: GZSP losses larger than last quarter! Genzyme is spinning their financial results to give the FALSE IMPRESSION that they are doing better now than before. However THEIR OWN FINANCIAL RECORDS prove otherwise. Is it any wonder that this stock keeps going down? Is it any wonder that its volume has dropped to anemic proportions? Is it any wonder that the CRIMINAL management at Biomatrix and the CRIMINAL management at Genzyme want to combine forces to better STEAL YOUR MONEY with their endless LIES, HYPE, and FALSE PROMISES. Investors, it is time to run for the hills from these CRIMINAL and FRAUDULENT stocks before you lose ALL the money you have naively placed in their SWINDLING hands. Title: Synvisc is a DANGEROUS product Not only are the side-effects of Synvisc more common than almost any other medical treatment (7%-10% adverse reactions by Biomatrix’s own data), they are extremely DANGEROUS and potentially LETHAL. This is why doctors refuse to use Synvisc and why Synvisc has no end-use demand. It is only the DISHONEST AND UNETHICAL accounting practices used by Biomatrix that gives the illusion of sales. In reality, these "sales" only represent a build-up of inventory. THIS IS A FACT! Title: Rejected Synvisc is being sold by bxm Aside from the ongoing FDA violations throughout the facility, Biomatrix had a near crisis involving its microbiology testing. It seems as though damn near every batch made of Synvisc or one of its components was FAILING its compliance test for "microbial contamination". To my understanding, MOST OF THESE CONTAMINATED BATCHES WERE RELEASED FOR PUBLIC CONSUMPTION DESPITE THEIR COMPLIANCE FAILURE. I have no way of knowing for certain because the decision to release these microbial contaminated batches was made solely by Dr. Balazs and his QA vp and kept in extreme secrecy. NO ONE ELSE WAS INVOLVED! Yet I do know that HUNDREDS OF MILLIONS OF DOLLARS WORTH of contaminated product WAS NOT DISCARDED! Now we are seeing ever increasing evidence of adverse reactions and inflamed knees upon injection of Synvisc. The decline in price will continue The financial institutions are trying DESPERATELY to dump their holdings of these 3 pathetic and over valued stocks. BXM is a single digit stock that is slowly finding its way back down to its fair value. GZTR and GZSP are both penny stocks that aren’t worth anything over $3. All three of these stocks have been so HYPED by "pump and dump"ers that they are all currently selling 2-3 times the price that they should be. As the "pushers" on this board keep telling investors to "buy in the dips", they fail to mention that these aren’t "dips". They are only brief pauses in the steady decline back down to their fair values. The financial institutions just hope that there are enough SUCKERS out there that believe all the FALSE PROMISES made by ethicless "pushers". By June, the "merger" will have fallen through and all 3 of these worthless stocks will have found new 52 week lows. Remember, THERE WILL BE NO MERGER! And these 3 stocks will only decline further. (continued...)